Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
about
Interleukin-6: a new therapeutic targetBiologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisTocilizumab for rheumatoid arthritisComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyInterleukin-7 deficiency in rheumatoid arthritis.Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis.Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cellsLevels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis.Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritisInterleukin-6: an emerging regulator of pathological painRole of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathiesModulation of host cell signaling pathways as a therapeutic approach in periodontal diseaseLung disease in rheumatoid arthritisBlocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementAdalimumab for the treatment of rheumatoid arthritisComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisBiologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Medical management of Crohn's disease: current therapy and recent advances.Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularizationSystematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis.A role for the high-density lipoprotein receptor SR-B1 in synovial inflammation via serum amyloid-A.Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsEarly administration of IL-6RA does not prevent radiation-induced lung injury in miceSix-transmembrane epithelial antigen of prostate4 (STEAP4) is a tumor necrosis factor alpha-induced protein that regulates IL-6, IL-8, and cell proliferation in synovium from patients with rheumatoid arthritis.Circulating and synovial antibody profiling of juvenile arthritis patients by nucleic acid programmable protein arraysTofacitinib for the treatment of rheumatoid arthritis.Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of micegp130 at the nexus of inflammation, autoimmunity, and cancer.Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of tThe arthritis severity locus Cia5a regulates the expression of inflammatory mediators including Syk pathway genes and proteases in pristane-induced arthritis.Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70TNFα promotes Th17 cell differentiation through IL-6 and IL-1β produced by monocytes in rheumatoid arthritis.Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialAdvanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end product-mediated activation of mitogen-activated protein kinases and nuclear factor-κB in human osteoarthritis chondrocyt
P2860
Q21195659-014BA833-E2FC-477E-9372-01D92B9FB3B0Q24185797-E5C060B4-51A4-48B2-9A49-DD295A215B58Q24234126-755BE7D7-F3B9-4DF3-A412-E78D6BBAF418Q24630541-EC11C0BE-B8DE-4135-92C8-0C2FA4A78306Q24799450-3F1E5E80-52EB-4974-A447-95106B3763B9Q24812290-431D13F9-31C2-4D13-A48B-2E914FC127F3Q24812982-8B37A7F3-ABB1-423B-AA43-88921F05D979Q24816519-3380F911-5F25-4190-9FD4-E416B5685F5DQ26746659-1B65BE40-20CD-4F47-8E1B-1F6BF2D042E9Q26748646-7205DC99-AB0C-4467-9D7E-4DEFB15E2E13Q26830775-4F672693-4709-4399-9AC6-0B916BBEC5F2Q26852727-F2A3F520-0E1A-438D-A3AD-2A10BCA4B2A5Q26853575-AE61C2F5-C8AE-434A-989B-27B37CA97A81Q27021115-6BA946B1-A6E4-477B-B4BB-CFA81051AB60Q28282655-FD4A90C1-5307-45DB-966E-6F04AED8D9CDQ28547851-4D86BD49-90B6-47E8-ADC7-E290197F81EFQ30235341-EE6A0E1F-FF7D-4492-AD9A-524B8FB90B52Q30450875-114FD8B3-3654-4C01-852F-F2A30E676967Q31039549-FC75483B-2440-4866-BFEF-5BD7CF7988E8Q33285746-AB740D1A-EE4E-4FD5-933D-3B53CECAE83AQ33400381-89772895-9D01-4F59-9278-27028FF977ADQ33686973-0D7218D2-CECD-4774-A903-3F8591C2DA2DQ33745289-E42B6924-8697-4B3B-BD0C-58DED3A2410BQ33802181-B115DA71-5392-43BB-8951-D6E44B76DEC7Q33809045-879430A4-ED41-48EF-AC9F-CEF110CBD534Q33828652-1AB78FC0-1628-4E22-9336-FE756EC37C30Q34189142-16E3F5CD-DA88-4E23-ACE1-CD181CE3AA47Q34236133-5D1733D2-D480-4D59-8C72-B9367AFF3542Q34275878-EC904B2B-483C-4559-964B-6F819772CC23Q34343286-EA85DA3F-2BA8-4278-B36C-1C8B0F1DFD4CQ34363191-3AAFB4B2-9F05-4922-AA1D-CDF721D0E606Q34378756-209C288E-B84D-4AB0-913B-8B6B219331CDQ34394122-2534303D-FFC2-4B37-9F20-7D0B61F23711Q34515149-50089D7A-41D9-4AC5-BAEE-95B94E544BAFQ34523450-69F67356-8B73-4D79-9332-7D6E7D53A7D4Q34570319-E43F0379-6D17-4B67-BAC2-FE01E8759ED2Q34621516-1AE32E4D-B3C5-41CA-95E2-725AC3197872Q34768442-61664FC1-5150-4422-B599-3D7A12FEDD96Q34795777-90B4D494-E193-4CD2-B34A-0A0BF8D6EF0DQ34802374-7C841EE4-5A49-4801-99BD-11F137C8FFEA
P2860
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@en
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@nl
type
label
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@en
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@nl
prefLabel
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@en
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@nl
P2093
P921
P356
P1476
Treatment of rheumatoid arthri ...... ind, placebo-controlled trial.
@en
P2093
Jun Hashimoto
Junichi Azuma
Kazuhiko Yamamoto
Kazuyuki Yoshizaki
Nobuyuki Miyasaka
Norihiro Nishimoto
Shinichi Kawai
Tadamitsu Kishimoto
P304
P356
10.1002/ART.20303
P577
2004-06-01T00:00:00Z